Search

Your search keyword '"Steeghs N"' showing total 464 results

Search Constraints

Start Over You searched for: Author "Steeghs N" Remove constraint Author: "Steeghs N" Search Limiters Full Text Remove constraint Search Limiters: Full Text
464 results on '"Steeghs N"'

Search Results

3. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes

9. Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients

10. Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients

11. Referral patterns of GIST patients: data from a nationwide study

15. Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (Nature Communications, (2020), 11, 1, (728), 10.1038/s41467-019-13825-8)

16. Local recurrence in primary localised resected gastrointestinal stromal tumours: A registry observational national cohort study including 912 patients.

17. Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.

18. A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors.

19. Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).

20. Local treatment in metastatic GIST patients: A multicentre analysis from the Dutch GIST Registry.

21. The association of having a monitoring or blunting coping style with psychological distress, health-related quality of life and satisfaction with healthcare in gastrointestinal stromal tumour (GIST) patients.

22. The use of microtracers in food-effect trials : An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib

23. The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib

24. Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

25. Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT-enhanced estimate of renal function

27. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

28. 147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer

29. Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

30. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study

31. OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer

33. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

35. Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer

38. Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer

39. Is age just a number? A population pharmacokinetic study of gemcitabine

40. Sample Bias in Web-Based Patient-Generated Health Data of Dutch Patients With Gastrointestinal Stromal Tumor: Survey Study

41. Detection and localization of early- and late-stage cancers using platelet RNA

42. The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview

43. Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients

44. Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data

45. Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer

46. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

47. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study

48. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.

49. Sex differences in patients with gastrointestinal stromal tumours:do they exist and does it affect survival?

50. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics

Catalog

Books, media, physical & digital resources